A Phase 2 interventional study of pemetrexed and erlotinib in Non-Small-Cell Lung Cancer, sponsored by Eli Lilly and Company. Completed at 29 sites in 7 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2013-02-13.
Sponsored by Eli Lilly and Company · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 227 studies testing pemetrexed in Carcinoma, Non-Small-Cell Lung — 21 open to participants now, 32 under way, 11 of them phase 3. Pemetrexed · Carcinoma, Non-Small-Cell Lung.
Among the 227 studies testing pemetrexed in Carcinoma, Non-Small-Cell Lung, this one is the 40th largest by enrollment of the 223 interventional ones that give a count, is one of 12 that started in 2007, is one of 128 in phase 2, and was the 64th registered.
7,624 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,838 are open to participants now.
Browse Carcinoma, Non-Small-Cell Lung studies →21 of the 227 studies testing pemetrexed in Carcinoma, Non-Small-Cell Lung are open now, in 12 countries. Recruiting first, the newest first:
AstraZeneca · Sites in United States, Belgium, Brazil and 17 more countries
Ages 18+
Guangzhou Medical University · Sites in China
Ages 18–75
Second Affiliated Hospital of Nanchang University · Sites in China
Ages 18–85
Shanghai Chest Hospital · Sites in China
Ages 18+
Taipei Veterans General Hospital, Taiwan · Sites in Taiwan
Ages 20+
By country, each count listing its studies:
Pemetrexed: first FDA approval 2004 (ALIMTA), first EMA approval 2004. What it is approved for, and how studies give it, is on its page →
Of the 1,325 Carcinoma, Non-Small-Cell Lung studies recruiting now, 988 (75%) set no upper age limit and 224 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
227 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 39 · Phase 2 148 · Phase 3 47 · Phase 4 8
First in 2001; this study’s year is marked. 12 started in 2007.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 247 is above the median of 62 across 6,024 interventional studies indexed under Carcinoma, Non-Small-Cell Lung.
Median enrollment 64 across the 223 interventional studies. Of the 161 that completed or were terminated, 89 (55%) have results posted.
This tab as a report to print or save as PDF → With an account.
76 of 227 have an industry lead sponsor. The 10 most frequent:
Eli Lilly and Company is the lead sponsor of 2,108 studies on the registry; 153 are open to participants now.
Of its 537 completed or terminated interventional studies of FDA-regulated products, 358 (67%) have results posted.
147 studies in Carcinoma, Non-Small-Cell Lung by Eli Lilly and Company: 6 open now, 20 under way, 6 of them phase 3. Of 121 finished, 81 (67%) have results posted.
Among the 147 studies in Carcinoma, Non-Small-Cell Lung by Eli Lilly and Company, this one is the 32nd largest by enrollment of the 139 interventional ones that give a count, is one of 9 that started in 2007, is one of 73 in phase 2, and was the 58th registered.
Eli Lilly and Company’s Carcinoma, Non-Small-Cell Lung studies by the year they started, since 2000.
7 of the studies testing pemetrexed in Carcinoma, Non-Small-Cell Lung that are under way reach primary completion within a year, 3 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04585490Phase 3Stanford UniversityAdaptive ctDNA-Based Personalization of Treatment During Consolidation Therapy in NSCLC | 2026-12 |
| NCT06417814Phase 3AstraZenecaA Study to Investigate the Efficacy and Safety of Dato-DXd With or Without Osimertinib Compared With Platinum Based Doublet Chemotherapy in Participants With EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer | 2027-01-11 |
| NCT03178552Phase 3Hoffmann-La RocheA Study to Evaluate the Efficacy and Safety of Multiple Targeted Therapies as Treatments for Participants With Non-Small Cell Lung Cancer (NSCLC) | 2027-06-30 |
| NCT05805631Taipei Veterans General Hospital, TaiwanIntrathecal Pemetrexed for Leptomeningeal Metastasis in EGFR-Mutant NSCLC | 2026-12-31 |
| NCT06440954Hunan Province Tumor HospitalEfficacy and Resistance Mechanisms of IP in NSCLC With Leptomeningeal Metastases | 2026-12-31 |
Add all 7 to your calendar (.ics) → With an account.
Among the 227 studies testing pemetrexed in Carcinoma, Non-Small-Cell Lung, from their registry updates:
Among Eli Lilly and Company’s 147 in Carcinoma, Non-Small-Cell Lung:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to compare the combination of erlotinib and pemetrexed versus either pemetrexed alone and erlotinib alone, in terms of progression-free survival (time until the objective worsening of the disease) in patients who have never smoked and have locally advanced or metastatic Nonsquamous Non-Small Cell Lung Cancer who have failed a first-line chemotherapy treatment.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Measurable disease
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Pemetrexed 500 milligrams per meter squared (mg/m\^2) of body surface area, administered by intravenous (IV) infusion on Day 1 plus erlotinib 150 mg orally once daily on Day 2 through Day 14 of each 21-day cycle until disease progression or unacceptable toxicity developed or up to 38 months.
Drug: pemetrexed · Drug: erlotinib
Erlotinib 150 mg, administered orally once daily in each 21-day cycle until disease progression or unacceptable toxicity developed or up to 38 months.
Drug: erlotinib
Pemetrexed 500 mg/m\^2 of body surface area, administered by IV infusion on Day 1 of each 21-day cycle until progression or unacceptable toxicity developed or up to 38 months.
Drug: pemetrexed
500 milligrams per meter squared (mg/m\^2), intravenous (IV), every (q) 21 days until progression or unacceptable toxicity develops
Also known as: LY231514, Alimta
150 mg, orally, once daily until progression or unacceptable toxicity develops
Progression-Free Survival (PFS)
PFS is defined as the time from randomization to the first date of progressive disease (PD; either objectively determined or clinical progression) or death from any cause. PD was defined as at least a 20% increase in sum of longest diameter of target lesions as assessed by Response Evaluation Criteria in Solid Tumors (RECIST) version 1.0 guidelines. Time to disease progression was censored at the date of death.
Time frame: Randomization to measured PD up to 38 months
Percentage of Participants With a Tumor Response of Complete Response (CR) or Partial Response (PR) [Tumor Response Rate (TRR)]
TRR was defined as the number of responders (complete or partial) divided by the number of participants qualified for tumor response, as assessed using the RECIST version 1.0 guideline, multiplied by 100. RECIST guidelines: CR was defined as the disappearance of all target and non-target lesions and any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \<10 millimeter (mm) and normalization of tumor marker level of non-target lesions; PR was defined as at least a 30% decrease in sum of longest diameter of target lesions.
Time frame: Randomization to measured disease progression up to 38 months
Overall Survival (OS)
OS is defined as the time from randomization to the date of death from any cause.
Time frame: Baseline to date of death from any cause up to 45.5 months
Number of Participants With Adverse Events
A summary of serious and all other non-serious adverse events (AEs), which include AEs reported for pharmacological toxicity, is located in the Reported Adverse Event module.
Time frame: Randomization up to 39 months
Percentage of Participants With CR, PR, and Stable Disease (SD) - Disease Control Rate (DCR)
DCR was defined as the percentage of participants with CR, PR, or SD divided by the number of randomized and treated participants as assessed using the RECIST criteria. CR was defined as the disappearance of all target lesions; PR was defined as 1) at least a 30% decrease in sum of longest diameter of target lesions or 2) complete disappearance of target lesions, with persistence (but not worsening) of 1 or more non-target lesions; PD was defined as at least a 20% increase in sum of longest diameter of target lesions; SD was defined as small changes that did not meet the above criteria.
Time frame: Randomization to disease progression up to 38 months
Time to Worsening of Symptoms (TWS) on Lung Cancer Symptoms Scale (LCSS)
TWS assessed using the LCSS a participant rated lung cancer instrument which consisted of 9 disease related symptoms and quality of life (QoL) items, with 6 subscales related to major lung cancer symptoms (appetite, cough, fatigue, dyspnea, hemoptysis, and pain) and 3 summation items related to QoL (activity status, symptomatic distress, and overall QoL). Each item is marked on a visual analog scale (VAS) 0 (low symptoms/QoL items) to 100 (high symptoms/QoL items). The mean of the 6 subscales is used to calculate the average symptom burden index. TWS was measured from the date of study enrollment to the first date of a worsening in any 1 of the 6 LCSS symptom-specific items (as defined by a VAS 15-mm increase from baseline in the patient-reported score for any of these 6 items).
Time frame: Randomization to first date of worsening of any of 6 LCSS symptom specific items or up to 12.4 months
Number of Participants With Mutated or Non-Mutated Epidermal Growth Factor Receptor (EGFR) Genotype Status
EGFR mutation status was defined as: participants with any mutations detected were categorized as mutated and participants without any mutations detected were categorized as non-mutated.
Time frame: Randomization to date of PD or death up to 38 months
Probability of OS at 12 Months
OS time is censored at the date of last contact for participants who were still alive or lost to follow-up.
Time frame: Month 12
| Milestone | Pemetrexed + Erlotinib | Erlotinib | Pemetrexed |
|---|---|---|---|
| Started | 81 | 82 | 84 |
| Qualified participants | 78 | 82 | 80 |
| Not discontinued at 18 months | 9 | 19 | 11 |
| Completed | 9 | 19 | 11 |
| Not completed | 72 | 63 | 73 |
| Withdrew: Death | 45 | 38 | 50 |
| Withdrew: Physician decision | 1 | 2 | 2 |
| Withdrew: Withdrawal by subject | 9 | 12 | 17 |
| Withdrew: Sponsor decision | 13 | 7 | 1 |
| Withdrew: Lost to follow-up | 4 | 4 | 3 |
PFS is defined as the time from randomization to the first date of progressive disease (PD; either objectively determined or clinical progression) or death from any cause. PD was defined as at least a 20% increase in sum of longest diameter of target lesions as assessed by Response Evaluation Criteria in Solid Tumors (RECIST) version 1.0 guidelines. Time to disease progression was censored at the date of death.
| months | Pemetrexed + Erlotinib | Erlotinib | Pemetrexed |
|---|---|---|---|
| Progression-Free Survival (PFS) | 7.4 (4.4 to 12.9) | 3.8 (2.7 to 6.3) | 4.4 (3.0 to 6.0) |
TRR was defined as the number of responders (complete or partial) divided by the number of participants qualified for tumor response, as assessed using the RECIST version 1.0 guideline, multiplied by 100. RECIST guidelines: CR was defined as the disappearance of all target and non-target lesions and any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \<10 millimeter (mm) and normalization of tumor marker level of non-target lesions; PR was defined as at least a 30% decrease in sum of longest diameter of target lesions.
| percentage of participants | Pemetrexed + Erlotinib | Erlotinib | Pemetrexed |
|---|---|---|---|
| Percentage of Participants With a Tumor Response of Complete Response (CR) or Partial Response (PR) [Tumor Response Rate (TRR)] | 44.7 | 29.3 | 10.0 |
OS is defined as the time from randomization to the date of death from any cause.
| months | Pemetrexed + Erlotinib | Erlotinib | Pemetrexed |
|---|---|---|---|
| Overall Survival (OS) | 20.5 (17.1 to 25.0) | 22.8 (18.2 to 29.5) | 17.7 (11.8 to 25.3) |
A summary of serious and all other non-serious adverse events (AEs), which include AEs reported for pharmacological toxicity, is located in the Reported Adverse Event module.
| participants | Pemetrexed + Erlotinib | Erlotinib | Pemetrexed |
|---|---|---|---|
| Serious Adverse Events | 25 | 18 | 22 |
| Other Non-Serious Adverse Events | 72 | 76 | 67 |
DCR was defined as the percentage of participants with CR, PR, or SD divided by the number of randomized and treated participants as assessed using the RECIST criteria. CR was defined as the disappearance of all target lesions; PR was defined as 1) at least a 30% decrease in sum of longest diameter of target lesions or 2) complete disappearance of target lesions, with persistence (but not worsening) of 1 or more non-target lesions; PD was defined as at least a 20% increase in sum of longest diameter of target lesions; SD was defined as small changes that did not meet the above criteria.
| percentage of participants | Pemetrexed + Erlotinib | Erlotinib | Pemetrexed |
|---|---|---|---|
| Percentage of Participants With CR, PR, and Stable Disease (SD) - Disease Control Rate (DCR) | 64.5 | 52.4 | 56.3 |
TWS assessed using the LCSS a participant rated lung cancer instrument which consisted of 9 disease related symptoms and quality of life (QoL) items, with 6 subscales related to major lung cancer symptoms (appetite, cough, fatigue, dyspnea, hemoptysis, and pain) and 3 summation items related to QoL (activity status, symptomatic distress, and overall QoL). Each item is marked on a visual analog scale (VAS) 0 (low symptoms/QoL items) to 100 (high symptoms/QoL items). The mean of the 6 subscales is used to calculate the average symptom burden index. TWS was measured from the date of study enrollment to the first date of a worsening in any 1 of the 6 LCSS symptom-specific items (as defined by a VAS 15-mm increase from baseline in the patient-reported score for any of these 6 items).
| months | Pemetrexed + Erlotinib | Erlotinib | Pemetrexed |
|---|---|---|---|
| Time to Worsening of Symptoms (TWS) on Lung Cancer Symptoms Scale (LCSS) | 1.0 (0.9 to 1.6) | 0.8 (0.8 to 1.2) | 1.5 (1.0 to 2.1) |
EGFR mutation status was defined as: participants with any mutations detected were categorized as mutated and participants without any mutations detected were categorized as non-mutated.
| participants | Pemetrexed + Erlotinib | Erlotinib | Pemetrexed |
|---|---|---|---|
| Mutated | 7 (7.1 to —) | 8 | 9 |
| Non-mutated | 10 | 6 | 3 |
| Mutation status unknown (treated as missing) | 5 | 2 | 3 |
OS time is censored at the date of last contact for participants who were still alive or lost to follow-up.
| percent chance of survival | Pemetrexed + Erlotinib | Erlotinib | Pemetrexed |
|---|---|---|---|
| Probability of OS at 12 Months | 40.2 (28.3 to 51.8) | 26.2 (17.2 to 36.1) | 18.1 (9.1 to 29.4) |
Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Pemetrexed + Erlotinib | — | 25/78 (32.1%) | 72/78 (92.3%) |
| Erlotinib | — | 18/83 (21.7%) | 76/83 (91.6%) |
| Pemetrexed | — | 22/80 (27.5%) | 67/80 (83.8%) |
| Event | Pemetrexed + Erlotinib | Erlotinib | Pemetrexed |
|---|---|---|---|
| DyspnoeaRespiratory, thoracic and mediastinal disorders | 2/78 | 6/83 | 1/80 |
| DiarrhoeaGastrointestinal disorders | 4/78 | 0/83 | 2/80 |
| HyponatraemiaMetabolism and nutrition disorders | 2/78 | 0/83 | 4/80 |
| PyrexiaGeneral disorders | 3/78 | 2/83 | 1/80 |
| NeutropeniaBlood and lymphatic system disorders | 0/78 | 0/83 | 3/80 |
| Back painMusculoskeletal and connective tissue disorders | 0/78 | 2/83 | 3/80 |
| Respiratory tract infectionInfections and infestations | 0/78 | 3/83 | 0/80 |
| AstheniaGeneral disorders | 2/78 | 2/83 | 1/80 |
| PneumoniaInfections and infestations | 2/78 | 1/83 | 1/80 |
| SepsisInfections and infestations | 2/78 | 0/83 | 1/80 |
| Event | Pemetrexed + Erlotinib | Erlotinib | Pemetrexed |
|---|---|---|---|
| RashSkin and subcutaneous tissue disorders | 41/78 | 43/83 | 8/80 |
| DiarrhoeaGastrointestinal disorders | 29/78 | 29/83 | 8/80 |
| CoughRespiratory, thoracic and mediastinal disorders | 15/78 | 28/83 | 13/80 |
| VomitingGastrointestinal disorders | 25/78 | 10/83 | 12/80 |
| Dry skinSkin and subcutaneous tissue disorders | 12/78 | 25/83 | 2/80 |
| Decreased appetiteMetabolism and nutrition disorders | 23/78 | 15/83 | 19/80 |
| NauseaGastrointestinal disorders | 21/78 | 10/83 | 17/80 |
| FatigueGeneral disorders | 20/78 | 9/83 | 17/80 |
| PruritusSkin and subcutaneous tissue disorders | 17/78 | 20/83 | 4/80 |
| Neutrophil count decreasedInvestigations | 16/78 | 1/83 | 7/80 |
| Age Continuous(years) | Pemetrexed + Erlotinib | Erlotinib | Pemetrexed | Total |
|---|---|---|---|---|
| Mean | 56.0 ± 11.72 | 53.9 ± 10.49 | 56.1 ± 13.04 | 55.3 ± 11.78 |
| Sex: Female, Male(Participants) | Pemetrexed + Erlotinib | Erlotinib | Pemetrexed | Total |
|---|---|---|---|---|
| Female | 58 | 54 | 45 | 157 |
| Male | 20 | 28 | 35 | 83 |
| Race/Ethnicity, Customized(participants) | Pemetrexed + Erlotinib | Erlotinib | Pemetrexed | Total |
|---|---|---|---|---|
| Caucasian | 18 | 6 | 11 | 35 |
| African | 2 | 0 | 1 | 3 |
| East Asian (enrolled in an East Asian country) | 41 | 49 | 43 | 133 |
| East Asian (enrolled in non-East Asian Country) | 4 | 2 | 1 | 7 |
| West Asian | 13 | 25 | 24 | 62 |
| Region of Enrollment(participants) | Pemetrexed + Erlotinib | Erlotinib | Pemetrexed | Total |
|---|---|---|---|---|
| Australia | 3 | 0 | 0 | 3 |
| Brazil | 15 | 5 | 8 | 28 |
| China | 14 | 17 | 15 | 46 |
| Hong Kong | 0 | 3 | 2 | 5 |
| India | 15 | 27 | 25 | 67 |
| Korea, Republic of | 20 | 20 | 13 | 53 |
| Taiwan | 7 | 9 | 13 | 29 |
| United Kingdom | 4 | 1 | 4 | 9 |
| Height at Baseline(centimeter (cm)) | Pemetrexed + Erlotinib | Erlotinib | Pemetrexed | Total |
|---|---|---|---|---|
| Mean | 159.3 ± 8.70 | 160.3 ± 8.38 | 160.1 ± 8.84 | 159.9 ± 8.61 |
| Weight at Baseline(kilogram (kg)) | Pemetrexed + Erlotinib | Erlotinib | Pemetrexed | Total |
|---|---|---|---|---|
| Mean | 59.6 ± 11.76 | 59.9 ± 12.17 | 58.9 ± 10.82 | 59.5 ± 11.56 |
| Body Mass Index (BMI)(kilogram per meter squared (kg/m^2)) | Pemetrexed + Erlotinib | Erlotinib | Pemetrexed | Total |
|---|---|---|---|---|
| Mean | 23.5 ± 4.54 | 23.3 ± 3.87 | 23.0 ± 3.87 | 23.2 ± 4.09 |
| Body Surface Area (BSA)(meter squared (m^2)) | Pemetrexed + Erlotinib | Erlotinib | Pemetrexed | Total |
|---|---|---|---|---|
| Mean | 1.6 ± 0.17 | 1.6 ± 0.18 | 1.6 ± 0.17 | 1.6 ± 0.17 |
2 further baseline measures are reported on the registry.
The record gives a start of Nov 2007, a primary completion of Jan 2012 and a completion of Jan 2012. It does not say whether these dates are actual or estimated.
Results were first posted in Feb 2013, 1 year 1 month after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jan 2013. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Pemetrexed · Erlotinib
Carcinoma, Non-Small-Cell Lung →